Schoof, NilsNilsSchoofvon Bonin, FrederikeFrederikevon BoninZeynalova, SamiraSamiraZeynalovaZiepert, MaritaMaritaZiepertJung, WernerWernerJungLoeffler, MarkusMarkusLoefflerPfreundschuh, MichaelMichaelPfreundschuhTruemper, Lorenz H.Lorenz H.TruemperKube, DieterDieterKube2018-11-072018-11-072009https://resolver.sub.uni-goettingen.de/purl?gro-2/56423Methods: In 228 DLBCL samples of the German High-Grade Non-Hodgkin's Lymphoma Study Group, the polymorphisms of IL4 (-524CT, rs2243250), IL13 (-1069CT, rs1800925) and IL4R (I75V, rs1805010; S503P, rs1805015; Q576R, rs1801275) were analyzed and the soluble interleukin-4 receptor (sIL4R) serum level was measured before the start of chemotherapy. Results: Patients harboring IL4R V75 (IL4R(I75V-AG) and IL4R(I75V-GG)) had shorter overall survival (OS) (P = 0.044) and event-free survival (EFS) (P = 0.056) periods compared with I75 carriers (IL4R(I75V-AA)). Multivariate analysis adjusted to the International Prognostic Index revealed a relative risk of 1.9 for carriers of the IL4R V75 (P = 0.011) in relation to OS. DLBCL patients homozygous for the IL4R I75 and low sIL4R serum levels have the most favorable OS and EFS. Conclusions: These data support the role for host germline gene variations of immunologically important factors like the IL4R I75V gene variation to predict the survival in DLBCL patients.Goescholarhttps://goescholar.uni-goettingen.de/licenseFavorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trialjournal_article10.1093/annonc/mdp11019515749000269955700014https://resolver.sub.uni-goettingen.de/purl?gs-1/6327